BioKansas, a pivotal organization dedicated to supporting the bioscience sector in Kansas and the surrounding region, appoints Kevin Mills as its new President & CEO.
Mills, who brings to the table a profound depth of experience spanning over two decades in the bioscience and pharmaceutical industries, steps into his new role with a wealth of knowledge and expertise.
Before his appointment at BioKansas, Mills co-founded ZubiBio, where he has contributed significantly since January 2023, and has been actively involved with Cyteir Therapeutics since June 2012. These roles underscore his leadership in innovative bioscience ventures and his commitment to advancing healthcare solutions.
Notably, Mills served as Chief Scientific Officer at the National Hemophilia Foundation, where he played a crucial role in spearheading initiatives aimed at finding cures for inheritable blood disorders and enhancing the quality of life for affected individuals and families through research, education, and advocacy.
Mills’ career is distinguished by his contributions to the bioscience community, including key positions where he demonstrated exceptional skills in public speaking, strategy, fundraising, management, team building, drug development, life sciences, and mentoring
